Financial Engines Advisors L.L.C. Bristol Myers Squibb CO Transaction History

Financial Engines Advisors L.L.C.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $144,470 - $172,393	2,980 Added 71.91%	7,124 $365,000
Q3 2023 Nov 09, 2023	BUY	$57.89 - $64.73 $239,896 - $268,241	4,144 New	4,144 $240,000
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $28,830 - $34,138	-421 Reduced 10.94%	3,428 $246,000
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $63 - $37,574	-489 Reduced 11.27%	3,849 $273,000
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $24,037 - $26,473	-331 Reduced 7.09%	4,338 $335,000
Q1 2022 May 12, 2022	BUY	$61.48 - $73.72 $68,304 - $81,902	1,111 Added 31.23%	4,669 $343,000
Q4 2021 Feb 10, 2022	SELL	$53.63 - $62.52 $47,891 - $55,830	-893 Reduced 20.06%	3,558 $222,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $18,816 - $22,040	-318 Reduced 6.67%	4,451 $265,000
Q2 2021 Aug 12, 2021	SELL	$61.91 - $67.42 $100,727 - $109,692	-1,627 Reduced 25.44%	4,769 $319,000
Q1 2021 May 12, 2021	BUY	$59.34 - $66.74 $123,842 - $139,286	2,087 Added 48.43%	6,396 $406,000
Q4 2020 Feb 11, 2021	BUY	$57.74 - $65.43 $248,801 - $281,937	4,309 New	4,309 $269,000
Q4 2018 Feb 08, 2019	SELL	$48.76 - $63.23 $5,119 - $6,639	-105 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$55.19 - $62.25 $110 - $124	2 Added 1.94%	105 $7,000
Q2 2018 Jul 27, 2018	BUY	$50.53 - $62.98 $5,204 - $6,486	103 New	103 $6,000
Q1 2018 May 02, 2018	SELL	$59.92 - $68.98 $1,018 - $1,172	-17 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$59.94 - $65.35 $1,018 - $1,110	17	17 $1,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Financial Engines Advisors L.L.C., based on Form 13F filings with the SEC.

Stay updated on Financial Engines Advisors L.L.C. with notifications on news.